Skip to main content

Advertisement

SpringerLink
Log in

Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes

  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

Patients with the metabolic syndrome are insulin resistant and manifest a cluster of risk factors for cardiovascular disease. Impaired fibrinolysis and increased concentrations in blood of plasminogen activator inhibitor-1 (PAI-1) are related to insulin resistance and abdominal obesity and may contribute to the increased risk for cardiovascular disease in this group. Weight loss, metformin, and thiazolidinediones ameliorate insulin resistance and decrease concentrations of PAI-1. Thus, they may lower risk in patients with the metabolic syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Reaven GM: Role of insulin resistance in human disease. Diabetes 1988, 37:1595–1607.

    Article  PubMed  CAS  Google Scholar 

  2. Kahn R, Buse J, Ferrannini E, Stern M: The Metabolic syndrome: time for a critical appraisal. Diabetes Care 2005, 28:2289–2304. The ongoing debate about the nature of the metabolic syndrome is thoroughly reviewed in this paper.

    Article  PubMed  Google Scholar 

  3. Gale E: The myth of the metabolic syndrome. Diabetologia 2005, 48:1679–1683.

    Article  PubMed  Google Scholar 

  4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summar y of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486–2497.

    Article  Google Scholar 

  5. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15:539–553.

    Article  PubMed  CAS  Google Scholar 

  6. Dekker J, Girman C, Rhodes T, et al.: Metabolic syndrome and 10-year cardiovascular disease risk. Circulation 2005, 112:666–673.

    Article  PubMed  Google Scholar 

  7. Ford ES, Giles WH, Dietz WH: A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care 2003, 26:575–581.

    Article  PubMed  Google Scholar 

  8. Alexander CM, Landsman PB, Teutsch SM, et al.: NCEPde fined metabolic syndrome, diabetes and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003, 52:1210–1214.

    Article  PubMed  CAS  Google Scholar 

  9. Anand S, Yi Q, Gerstein H, et al.: Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 2003, 108:420–425.

    Article  PubMed  CAS  Google Scholar 

  10. Bonora E, Kiechl S, Willeit J, et al.: Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998, 47:1643–1649.

    Article  PubMed  CAS  Google Scholar 

  11. Lee Y, Pratley R: The evolving role of inf lammation in obesity and the metabolic syndrome. Curr Diab Rep 2005, 5:70–75.

    PubMed  CAS  Google Scholar 

  12. Kershaw EE, Flier JS: Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89:2548–2556.

    Article  PubMed  CAS  Google Scholar 

  13. Rajala MW, Scherer PE: Minireview: The adipocyte—at the crossroads of energy homeostasis, infiammation and atherosclerosis. Endocrinology 2003, 144:3765–3773.

    Article  PubMed  CAS  Google Scholar 

  14. Lakka HM, Laaksonen DE, Lakka TA, et al.: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 285:2709–2716.

    Article  Google Scholar 

  15. Levantesi G, Macchia A, Marfisi R, et al.: Metabolic syndrome and risk of cardiovascular events after myocardial infarction. J Am Coll Cardiol 2005, 46:277–283.

    Article  PubMed  Google Scholar 

  16. Malik S, Wong ND, Franklin SS: Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004, 110:1245–1250.

    Article  PubMed  Google Scholar 

  17. Isomaa B, Almgren P, Tuomi T, et al.: Cardiovascular morbidity and mortality with the metabolic syndrome. Diabetes Care 2001, 24:683–689.

    Article  PubMed  CAS  Google Scholar 

  18. Saely SH, Aczel S, Marte T, et al.: The metabolic syndrome is gradually and independently predictive for vascular events among patients undergoing coronary artery angiography [abstract]. J Am Coll Cardiol 2005, 45(suppl):803–806.

    Google Scholar 

  19. Kannel WB, McGee DL: Diabetes and cardiovascular risk factors: the Framingham study. Circulation 1979, 59:8–13.

    PubMed  CAS  Google Scholar 

  20. Wilson PW, Cupples LA, Kannel WB: Is hyperglycemia associated with cardiovascular disease? The Framingham Study. Am Heart J 1991, 121(2 Pt 1):586–590.

    Article  PubMed  CAS  Google Scholar 

  21. Iribarren C, Karter AJ, Go AS, et al.: Glycemic control and heart failure among adult patients with diabetes. Circulation 2001, 103:2668–2673.

    PubMed  CAS  Google Scholar 

  22. Alberti KG: Impaired glucose tolerance: what are the clinical implications? Diabetes Res Clin Pract 1998, 40(Suppl):S3-S8.

    PubMed  Google Scholar 

  23. Eschwege E: The dysmetabolic syndrome, insulin resistance and increased cardiovascular (CV) morbidity and mortality in type 2 diabetes: aetiological factors in the development of CV complications. Diabetes Metab 2003, 29(4 Pt 2):6S19–6S27.

    Article  PubMed  CAS  Google Scholar 

  24. Fisman EZ, Motro M, Tenenbaum A, et al.: Impaired fasting glucose concentrations in nondiabetic patients with ischemic heart disease: a marker for worse prognosis. Am Heart J 2001, 141:485–490.

    Article  PubMed  CAS  Google Scholar 

  25. Kohler HP, Grant PJ: Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000, 342:1792–1801.

    Article  PubMed  CAS  Google Scholar 

  26. Despres JP, Lamarche B, Mauriege P, et al.: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996, 334:952–957.

    Article  PubMed  CAS  Google Scholar 

  27. Haffner SM, Mykkanen L, Stern MP, et al.: Relationship of proinsulin and insulin to cardiovascular risk factor in nondiabetic subjects. Diabetes 1993, 42:1297–1302.

    Article  PubMed  CAS  Google Scholar 

  28. Hoffmeister A, Rothenbacher D, Bazner U, et al.: Role of novel markers of in.ammation in patients with stable coronary heart disease. Am J Cardiol 2001, 87:262–266.

    Article  PubMed  CAS  Google Scholar 

  29. Howard G, O’Leary DH, Zaccaro D, et al.: Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study Investigators. Circulation 1996, 93:1809–1817.

    PubMed  CAS  Google Scholar 

  30. Marte T, Drexel H, Aczel S, et al.: Insulin resistance is an independent predictor of vascular events in diabetic patients with angiographically proven stable coronary artery disease [abstract]. J Am Coll Cardiol 2005, 45(suppl):1035–1229.

    Google Scholar 

  31. Nilsson P, Nilsson JA, Hedblad B, et al.: Hyperinsulinemia as long-term predictor of death and ischaemic heart disease in non-diabetic men: the Malmo Preventive Project. J Intern Med 2003, 253:136–145.

    Article  PubMed  CAS  Google Scholar 

  32. Saito I, Folsom AR, Brancati FL, et al.: Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Ann Intern Med 2000, 133:81–91.

    PubMed  CAS  Google Scholar 

  33. Torr-Brown SR, Sobel BE: Plasminogen activator in inhibitor is elevated in plasma and diminished in platelets in patients with diabetes mellitus. Thromb Res 1994, 75:473–477.

    Article  PubMed  CAS  Google Scholar 

  34. Schneider DJ, Absher PM, Neimane D, et al.: Fibrinolysis and atherogenesis in the JCR:LA-cp rat in relation to insulin and triglyceride concentrations in blood. Diabetologia 1998, 41:141–147.

    Article  PubMed  CAS  Google Scholar 

  35. Schneider DJ, Ricci MA, Taatjes DJ, et al.: Changes in arterial expression of fibrinolytic system proteins in atherogenesis. Arterioscler Thromb Vasc Biol 1997, 17:3294–3301.

    PubMed  CAS  Google Scholar 

  36. Sobel BE: The potential inf luence of insulin and plasminogen activator inhibitor type 1 on the formation of vulnerable atherosclerotic plaques associated with type 2 diabetes. Proc Assoc Am Physicians 1999, 111:313–318.

    Article  PubMed  CAS  Google Scholar 

  37. Nordt T, Klassen KJ, Schneider DJ, et al.: Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Arterioscler Thromb 1993, 13:1822–1828.

    PubMed  CAS  Google Scholar 

  38. Meigs JB, Mittleman MA, Nathan DM, et al.: Hyperinsulinemia, hyperglycemia and impaired hemostasis. The Framingham Offspring Study. JAMA 1999, 19:605–610.

    Google Scholar 

  39. Vague PH, Juhan-Vague I, Aillaud MF, et al.: Correlation between blood fibrinolytic activity, PA-inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism 1986, 35:350–353.

    Article  Google Scholar 

  40. Mertens I, Van Gaal L: Obesity, hemostasis and the fibrinolytic system. Obes Rev 2002, 3:85–101.

    Article  PubMed  CAS  Google Scholar 

  41. Konstantinides S, Schafer K, Thinnes T, et al.: Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after vascular injury in mice. Circulation 2001, 103:576–583.

    PubMed  CAS  Google Scholar 

  42. Skurk T, Hauner H: Obesity and impaired fibrinolysis: Role of adipose production of plasminogen activator inhibitor-1. Int J Obes 2004, 28:1357–1364. A thorough review of the regulation of PAI-1 in adipocytes.

    Article  CAS  Google Scholar 

  43. Godsland I, Crook D, Proudler A, Stevenson J: Hemostatic risk factors and insulin sensitivity, regional body fat distribution and the metabolic syndrome. J Clin Endocrinol Metab 2005, 90:190–197.

    Article  PubMed  CAS  Google Scholar 

  44. Soderberg S, Olsson T, Eliassson M, et al.: Plasma leptin levels are associated with abnormal fibrinolysis in men and postmenopausal women. J Intern Med 1999, 245:533–543.

    Article  PubMed  CAS  Google Scholar 

  45. McGill JB, Schneider DJ, Arfken CL, et al.: Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1993, 43:104–109.

    Article  Google Scholar 

  46. Nagi D, Tracy R, Pratley R: Relationship of hepatic and peripheral insulin resistance with plasminogen activator inhibitor-1 in Pima Indians. Metabolism 1996, 10:1243–1247.

    Article  Google Scholar 

  47. Calles-Escandon J, Mirza SA, Sobel BE, et al.: Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes 1998, 47:290–293.

    Article  PubMed  CAS  Google Scholar 

  48. Gray RP, Panahloo A, Mohamed-Ali V, et al.: Proinsulin like molecules and plasminogen activator inhibitor type 1 (PAI1) activity in diabetic and non-diabetic subjects with and without myocardial infarction. Atherosclerosis 1997, 130:171–178.

    Article  PubMed  CAS  Google Scholar 

  49. Nordt T, Sawa H, Fujii S, et al.: Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation 1995, 91:764–770.

    PubMed  CAS  Google Scholar 

  50. Lee Y, Nair S, Rousseau E, et al.: Microarray profiling of isolated abdominal subcutaneous adipocytes from obese and non-obese Pima Indians: increased expression of inf lammation related genes. Diabetologia 2005, 48:1776–1783.

    Article  PubMed  CAS  Google Scholar 

  51. Lundgren CH, Brown SL, Nordt TK, et al.: Elaboration of type-1 plasminogen activator inhibitor from adipocytes. Circulation 1996, 93:106–110.

    PubMed  CAS  Google Scholar 

  52. Alessi MC, Peiretti F, Morange P, et al.: Production of plasminogen activator inhibitor-1 by human adipose tissue: possible link between visceral fat and vascular disease. Diabetes 1997, 46:860–867.

    Article  PubMed  CAS  Google Scholar 

  53. Eriksson P, Reynisdottir S, Lonnqvist F, et al.: Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. Diabetologia 1998, 41:65–71.

    Article  PubMed  CAS  Google Scholar 

  54. Mavri A, Alessi MC, Bastelica D, et al.: Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to PAI-1 levels and insulin resistance and decreases after weight loss. Diabetologia 2001, 44:2025–2031.

    Article  PubMed  CAS  Google Scholar 

  55. Shimomura I, Funahashi T, Takahashi M, et al.: Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996, 16:368–374.

    Google Scholar 

  56. Fattal PG, Schneider DJ, Sobel BE, et al.: Post-transcriptional regulation of expression of plasminogen activator inhibitor type 1 mRNA by insulin and insulin-like growth factor 1. J Biol Chem 1992, 267:12412–12415.

    PubMed  CAS  Google Scholar 

  57. Samad E, Uysal K, Weisbrock S, et al.: Tumor necrosis factor alpha is a key component in the obesity linked elevation of plasminogen activator inhibitor-1. Proc Natl Acad Sci U S A 1999, 96:6902–6907.

    Article  PubMed  CAS  Google Scholar 

  58. Skurk T, Lee Y, Hauner H: Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture. Hypertension 2001, 37:1336–1340.

    PubMed  CAS  Google Scholar 

  59. Weisberg SP, McCann D, Desai M, et al.: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796–1808.

    Article  PubMed  CAS  Google Scholar 

  60. Bastelica D, Morange P, Berthet B, et al.: Stromal cells are the main plasminogen activator inhibitor-1 producing cells in human fat: evidence of differences between visceral and subcutaneous deposits. Arterioscler Thromb Vasc Biol 2002, 22:173–178.

    Article  PubMed  CAS  Google Scholar 

  61. Hamsten A, Wiman B, de Faire U, et al.: Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985, 313:1557–1563.

    Article  PubMed  CAS  Google Scholar 

  62. Meade T, Ruddock V, Stirling Y, et al.: Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993, 342:1076–1079.

    Article  PubMed  CAS  Google Scholar 

  63. Hamsten A, de Faire U, Walldius G, et al.: Plasminogen activator inhibitor in plasma: risk for recurrent myocardial infarction. Lancet 1987, 2:3–9.

    Article  PubMed  CAS  Google Scholar 

  64. Thompson SG, Kienast J, Pike S, et al.: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995, 332:635–641.

    Article  PubMed  CAS  Google Scholar 

  65. Thogersen A, Jansson A, Boman K, et al.: High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998, 98:2241–2247.

    PubMed  CAS  Google Scholar 

  66. Sobel BE, Taatjes DJ, Schneider DJ: Intramural plasminogen activator inhibitor type-1 and coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2003, 23:1979–1989.

    Article  PubMed  CAS  Google Scholar 

  67. Sobel BE, Woodcock-Mitchell J, Schneider DJ, et al.: Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation 1998, 97:2213–2221.

    PubMed  CAS  Google Scholar 

  68. Gu K, Cowie CC, Harris MI: Diabetes and decline in heart disease mortality in US adults. JAMA 1999, 281:1291–1297.

    Article  PubMed  CAS  Google Scholar 

  69. Kuusisto J, Mykkanen L, Pyorala K, Laasko M: NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994, 43:960–967.

    Article  PubMed  CAS  Google Scholar 

  70. Haffner SM, Lehto S, Ronnemaa T, et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229–234.

    Article  PubMed  CAS  Google Scholar 

  71. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI) [no authors listed]. Circulation 1997, 96:1761–1769.

  72. Sobel BE: Increased plasminogen activator inhibitor-1 and vasculopathy: a reconcilable paradox. Circulation 1999, 99:2496–2498.

    PubMed  CAS  Google Scholar 

  73. Moreno PR, Murcia AM, Palacios IF, et al.: Coronar y composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 2000, 102:2180–2184.

    PubMed  CAS  Google Scholar 

  74. Schneider DJ, Hayes M, Wadsworth M, et al.: Attenuation of neointimal vascular smooth muscle cellularity in atheroma by plasminogen activator inhibitor type-1 (PAI-1). J Histochem Cytochem 2004, 52:1091–1099.

    Article  PubMed  CAS  Google Scholar 

  75. Moreno PR, Fallon JT, Murcia AM, et al.: Tissue characteristics of restenosis after percutaneous transluminal coronary angioplasty in diabetic patients. J Am Coll Cardiol 1999, 34:1045–1049.

    Article  PubMed  CAS  Google Scholar 

  76. Pandol. A, Cetrullo D, Polishuck R, et al.: Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects. Arterioscler Thromb Vasc Biol 2001, 8:1378–1382.

    Google Scholar 

  77. Clough MH, Schneider DJ, Sobel BE, et al.: Attenuation of accumulation of neointimal lipid by pioglitazone in mice genetically de.cient in insulin receptor substrate-2 and apolipoprotein E. J Histochem Cytochem 2005, 53:603–610.

    Article  PubMed  CAS  Google Scholar 

  78. Zhu T, Farrehi PM, Fay WP: Plasminogen activator inhibitor type 1 enhances neointima formation after oxidation vascular injury in atherosclerosis-prone mice. Circulation 2001, 103:3105–3110.

    PubMed  CAS  Google Scholar 

  79. Mavri A, Stegnar M, Krebs M, et al.: Impact of adipose tissue on plasminogen activator inhibitor-1 in dieting obese women. Arterioscler Thromb Vasc Biol 1999, 19:1582–1587.

    PubMed  CAS  Google Scholar 

  80. Janand-Delenne B, Chagnaud C, Raccah D, et al.: Visceral fat as a main determinant of plasminogen activator inhibitor-1 level in women. Int J Obes Relat Metab Disord 1998, 22:312–317.

    Article  PubMed  CAS  Google Scholar 

  81. Calles-Escandon J, Ballor D, Har vey-Berino J, et al.: Amelioration of the inhibition of fibrinolysis in elderly, obese subjects by moderate energ y intake restriction. Am J Clin Nutr 1996, 64:7–11.

    PubMed  CAS  Google Scholar 

  82. Zhang S, Day I, et al.: Nicotine induced changes in gene expression by human coronary artery endothelial cells. Atherosclerosis 2001, 154:277–283.

    Article  PubMed  CAS  Google Scholar 

  83. Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145–153.

    Article  PubMed  CAS  Google Scholar 

  84. Yusuf S, Gerstein H, Hoogwerf B, et al.: Ramipril and the development of diabetes. JAMA 2001, 286:1882–1885.

    Article  PubMed  CAS  Google Scholar 

  85. Vaughan DE, Rouleau JL, Ridker PM, et al.: Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. Heart Study Investigators. Circulation 1997, 96:442–447.

    PubMed  CAS  Google Scholar 

  86. Koh K, Chung W, Ahn J, et al.: Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo controlled study. Atherosclerosis 2004, 177:155–160.

    Article  PubMed  CAS  Google Scholar 

  87. Nagi DK, Yudkin JS: Effects of metformin on insulin-resistance for cardiovascular disease, and plasminogen activator inhibitor in NIDDM. Diabetes Care 1993, 16:621–629.

    Article  PubMed  CAS  Google Scholar 

  88. Ehrmann DA, Cavaghan MK, Imperial J, et al.: Effects of metformin on insulin secretion, insulin action and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997, 82:524–530.

    Article  PubMed  CAS  Google Scholar 

  89. Ehrmann DA, Schneider DJ, Sobel BE, et al.: Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997, 82:2108–2116.

    Article  PubMed  CAS  Google Scholar 

  90. Kruszynska YT, Yu JG, Olefsky JM, et al.: Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes 2000, 49:633–639.

    Article  PubMed  CAS  Google Scholar 

  91. Zirlik A, Leugers A, Lohrmann J, et al.: Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones. Thromb Haemost 2004, 91:674–682.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Diabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine, One South Prospect Street, 05401, Burlington, VT, USA

    Susanne Trost MD

Authors
  1. Susanne Trost MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard E. Pratley MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Burton E. Sobel MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susanne Trost MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trost, S., Pratley, R.E. & Sobel, B.E. Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes. Curr Diab Rep 6, 47–54 (2006). https://doi.org/10.1007/s11892-006-0052-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-006-0052-5

Keywords

Search

Navigation